Top
Main
 
All Outcomes
 
Feedback
Home
c19early.org COVID-19 treatment researchNitric OxideNitric Oxide (more..)
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta
Cannabidiol Meta Molnupiravir Meta
Colchicine Meta
Conv. Plasma Meta
Curcumin Meta Nigella Sativa Meta
Ensovibep Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Peg.. Lambda Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Ivermectin Meta
Lactoferrin Meta

Loading...

Supplementary Data — Nitric Oxide for COVID-19: real-time meta analysis of 10 studies

@CovidAnalysis, September 2023
https://c19early.org/nometa.html
 
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Winchester (DB RCT) 42% 0.58 [0.36-0.94] no improv. 8/15 23/25 Improvement, RR [CI] Treatment Control Winchester (DB RCT) 51% 0.49 [0.32-0.75] viral load 40 (n) 40 (n) Tandon (DB RCT) 42% 0.58 [0.33-1.01] no improv. 14/64 26/69 Tandon (DB RCT) 67% 0.33 [0.11-0.97] no improv. 4/64 13/69 Tandon (DB RCT) 68% 0.32 [0.09-1.12] no improv. 3/64 10/69 Tandon (DB RCT) 22% 0.78 [0.32-1.89] no improv. 8/105 10/102 Tandon (DB RCT) 18% 0.82 [0.39-1.75] no improv. 11/105 13/102 Tandon (DB RCT) 9% 0.91 [0.60-1.38] no improv. 30/105 32/102 Tandon (DB RCT) 20% 0.80 [0.75-0.86] viral load 64 (n) 69 (n) Tandon (DB RCT) 14% 0.86 [0.83-0.90] viral load 105 (n) 102 (n) Tandon (DB RCT) 26% 0.74 [0.52-1.05] viral time 64 (n) 69 (n) Tandon (DB RCT) 6% 0.94 [0.70-1.25] viral time 105 (n) 102 (n) Bryan (DB RCT) -1% 1.01 [0.21-4.95] progression 3/261 3/263 Bryan (DB RCT) 11% 0.89 [0.71-1.11] recov. time 261 (n) 263 (n) Chandel -54% 1.54 [0.72-2.78] death 12/66 36/206 Chandel -27% 1.27 [0.82-1.73] ventilation 29/66 79/206 Moni (RCT) 90% 0.10 [0.01-0.76] death 0/14 4/11 ICU patients Moni (RCT) 90% 0.10 [0.01-0.76] ventilation 0/14 4/11 ICU patients Moni (RCT) 42% 0.58 [0.05-1.00] no improv. 3/14 7/11 ICU patients Moni (RCT) 64% 0.36 [0.17-0.74] viral load 14 (n) 11 (n) ICU patients Moni (RCT) 63% 0.37 [0.18-0.75] viral load 14 (n) 11 (n) ICU patients Strickland (RCT) -179% 2.79 [0.12-64.0] ventilation 1/19 0/15 Strickland (RCT) 21% 0.79 [0.05-11.6] hosp. 1/19 1/15 Strickland (RCT) -38% 1.38 [0.50-3.85] misc. 7/19 4/15 Poonam 14% 0.86 [0.72-1.04] death 32/41 56/62 Ventilated patients OT​1​ Valsecchi 58% 0.42 [0.02-9.86] death 0/20 1/51 Valsecchi 68% 0.32 [0.08-1.26] ventilation 2/20 16/51 Valsecchi 39% 0.61 [0.27-1.39] ICU 5/20 21/51 Al Sulaiman (ICU) -40% 1.40 [0.94-2.11] death 44/56 52/125 ICU patients Al Sulaiman (ICU) -18% 1.18 [0.77-1.82] death 41/56 44/122 ICU patients SaNOtize 75% 0.25 [0.14-0.43] cases 13/203 108/422 Nitric oxide COVID-19 outcomes c19early.org Sep 2023 ​1​ OT: comparison with other treatment Favors nitric oxide Favors control
Figure S1. All outcomes.
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit